SCHEMBL12614743

SCHEMBL12614743

CCOC(=O)c1ccc(S(=O)(=O)NC)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.72
▸ GAA P10253 1/20 0.72
▸ NHERF1 O14745 1/20 0.63
▸ LMNA P02545 3/20 0.60
▸ ALDH1A1 P00352 3/20 0.60
▸ SMN1; SMN2 Q16637 2/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ MAPT P10636 2/20 0.60
▸ TSHR P16473 1/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.60
▸ HPGD P15428 2/20 0.58
▸ RECQL P46063 1/20 0.58
▸ KDM4E B2RXH2 3/20 0.56
▸ CA2 P00918 3/20 0.56
▸ CA1 P00915 2/20 0.56
▸ CA9 Q16790 2/20 0.56
▸ CA12 O43570 1/20 0.56
▸ ESR1 P03372 1/20 0.56
▸ CA7 P43166 1/20 0.56
▸ ESR2 Q92731 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9477242 0.85 KMT2A (0.70) KMT2AGAANHERF1LMNAALDH1A1
SCHEMBL16166426 0.85 KMT2A (0.70) KMT2AGAANHERF1LMNAALDH1A1
SCHEMBL18770380 0.83 KMT2A (0.51) KMT2AGAANHERF1LMNAALDH1A1
SCHEMBL2589383 0.83 KMT2A (0.67) KMT2AGAANHERF1LMNAALDH1A1
SCHEMBL10153945 0.82 CA1 (0.59) GAALMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL9417503 0.82 KMT2A (0.66) KMT2AGAANHERF1LMNAALDH1A1
SCHEMBL29504635 0.82 CA1 (0.79) KMT2AGAALMNAALDH1A1SMN1; SMN2
SCHEMBL63779 0.81 KMT2A (0.64) KMT2AGAANHERF1LMNAALDH1A1
SCHEMBL11292601 0.81 KMT2A (0.64) KMT2AGAANHERF1LMNAALDH1A1
SCHEMBL18770390 0.80 KMT2A (0.49) KMT2AGAANHERF1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169260-B2 Amidopyrazole inhibitors of interleukin receptor-associated kinases MERCK SHARP & DOHME CORP. (US) 2015-10-27 — — US disclosed
US-20140194404-A1 AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES MERCK SHARP & DOHME LLC 2014-07-10 — — US disclosed
EP-2688872-A1 AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES Merck Sharp & Dohme Corp. (US) 2014-01-29 — — EP disclosed
WO-2012129258-A1 AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES MERCK SHARP & DOHME CORP. (US) 2012-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194404-A1 AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES IRAK4, IRAK3, IRAK1 KMT2A 1386/4885GAA 3636/4885NHERF1 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback